Hoping for a COVID-19 antiviral that limits virus spread

Lauren Ancel Meyers, Zhanwei Du and Robert M. Krug
Published in Microbiology
Hoping for a COVID-19 antiviral that limits virus spread

Share this post

Choose a social network to share with, or copy the shortened URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

As the COVID-19 pandemic claims hundreds of thousands of lives and wreaks economic havoc worldwide, scientists are racing to develop antivirals that reduce the fatality of the disease. Our new study–Modelling mitigation of influenza epidemics by Baloxavirprojects the impacts of ramping up antiviral treatment during an emerging influenza epidemic, and compares an older antiviral (oseltamivir, Tamiflu) to a next generation antiviral (baloxavir, Xofluza). Our results for influenza suggest a critical priority for COVID-19 drug research and public health planning.

The upshot of our study is that some influenza antivirals can do far more than save the lives of treated patients. Baloxavir stops virus replication dead in its tracks, and, as a result, dramatically reduces the number of days a patient is contagious. In doing so, the drug not only helps the patient but also indirectly prevents the infection of others. We found that treating even 10% of infected patients with baloxavir shortly after the onset of their symptoms can indirectly prevent millions of infections and save thousands of lives during a typical influenza season. 

The development of a baloxavir-like drug for SARS-CoV-2 would be a game changer. Imagine a drug that quashes viral load within a day and thus radically shortens the contagious period. Basically, we could isolate COVID-19 cases pharmaceutically rather than physically, and thereby disrupt chains of transmission. 

What will it take to make such a drug a reality? 

Developing this type of drug is the hard part. Antiviral drug development has historically been slow and expensive. For this reason, COVID-19 investigators are prioritizing drugs that can be deployed quickly, without extensive clinical trials, to treat hospitalized patients with life-threatening symptoms. Promising candidates include nucleotide analogs that inhibit other RNA viruses (remdesivir, favipiravir), and FDA-approved drugs for treating other diseases. None of these candidates are likely to curtail viral replication as rapidly as baloxavir. Thus, a concerted effort to develop drugs directed at specific SARS-CoV2 proteins and functions is sorely needed.

Deploying such a drug may not be as simple as it seems. We may face a trade-off between its immediate therapeutic benefits and its capacity to prevent new infections. Treating a critically ill patient could be immediately life-saving, whereas treating a seemingly healthy patient shortly after infection (detected by a COVID-19 positive test) could block transmission to other people who might otherwise have ended up in the hospital or worse.

How can we prepare now to ensure that such drugs have the biggest possible impact?

SARS-CoV-2 is an elusive virus. Infected people are apparently contagious even before developing symptoms. The earlier a transmission-blocking drug is administered, the greater the inhibition of virus spread. We should be planning now for antiviral distribution channels that provide immediate access for individuals who test positive, even before symptoms develop. 

We previously published a strategy for pharmacy-based distributions of antivirals to ensure access for underinsured populations. Ongoing efforts to expand telemedicine and the distribution of diagnostics and drugs via the US Postal Service could further accelerate treatment in hard-to-reach rural populations. Finally, antiviral provisioning could be integrated into contact tracing programs. 

Any antiviral that proves effective against the SARS-CoV2 virus could save lives and avert costly lockdowns while we wait for an effective vaccine. However, an antiviral drug with baloxavir-like properties could radically change the course of the pandemic by simultaneously reducing the severity of illness and curbing virus spread.

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Subscribe to the Topic

Life Sciences > Biological Sciences > Microbiology

Related Collections

With collections, you can get published faster and increase your visibility.

Materials and devices for separation, sensing, and protection

In this Collection, the editors of Nature Communications and Communications Materials welcome the submission of primary research articles that highlight the development and application of functional materials in the areas of separation, sensing, and protection.

Publishing Model: Open Access

Deadline: Jun 30, 2024

Applied Sciences

This collection highlights research and commentary in applied science. The range of topics is large, spanning all scientific disciplines, with the unifying factor being the goal to turn scientific knowledge into positive benefits for society.

Publishing Model: Open Access

Deadline: Ongoing